Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
This is a randomized, multicenter phase 2 clinical trial to evaluate the efficacy and safety of capecitabine plus pyrotinib versus capecitabine plus trastuzumab plus pertuzumab in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.
Metastatic Breast Cancer
DRUG: Capecitabine and Pyrotinib|DRUG: Capecitabine,Trastuzumab, and Pertuzumab
Progression Free Survival, Approximately 42 months
Adverse Events and Serious Adverse Events, AEs+SAEs, From the first drug administration to within 28 days for the last treatment|Overall Survival, Up to 2 years|Objective Response Rate, Approximately 42 months|Duration of Objective Response, Approximately 42 months|Clinical Benefit rate, From the start of randomization to 6 months
This is a randomized, multicenter phase 2 clinical trial to evaluate the efficacy and safety of capecitabine plus pyrotinib versus capecitabine plus trastuzumab plus pertuzumab in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.